Data on cytokeratin-18 (K-18) and enhanced liver fibrosis (ELF) score in insulin-treated diabetes patients with non-alcoholic fatty liver disease (NAFLD) are limited. This study analyzed phase III data comparing basal insulin peglispro (BIL) and insulin glargine in type 1 (T1D), and type 2 diabetes (T2D) (insulin-naïve and insulin-treated). Alanine aminotransferase…
There has been a widespread misconception among physicians that African Americans are protected from developing nonalcoholic steatohepatitis (NASH). However, a formal histologic and metabolic comparison against well-matched Caucasians has never been performed. Read More: http://care.diabetesjournals.org/content/41/1/187.long Bril F, Portillo-Sanchez P, Liu IC, Kalavalapalli S, Dayton K,…
This study aimed to analyze adult kidney transplant recipients (KTRs) for the risk of new-onset diabetes after transplantation (NODAT) associated with viral serologies and immunosuppression regimens [tacrolimus (Tac) + mycophenolate (MPA), cyclosporine (CSA) + MPA, sirolimus (SRL) + MPA, SRL + CSA or SRL +Tac]. Read More: https://academic.oup.com/ndt/article/33/1/177/4554912 Santos AH JR, Chen C,…
ECHO Type 1 Diabetes is an 18-month pilot program, which is allowing researchers at the University of Florida and Stanford University to learn more about how to improve care access for underserved adult and pediatric communities living with Type 1 Diabetes (T1D).
UF Diabetes Institute Director: Mark Atkinson, Ph.D. The UF Diabetes Institute completed its third year in 2017, pushing forward toward its overarching mission to improve the lives of those living with diabetes so that we may one day see a diabetes-free world. With one new person diagnosed with diabetes every…
Medical News Today Article – Expert commentary by nPOD investigators. “The beauty of this approach is the virtual lack of any adverse effects, since it would use the patients’ own cells.” –Prof. Paolo Fiorina…
